ClinicalTrials.gov
public full text
Public Domain
Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III
This trial has been designed to prove the feasibility of using liquid biopsy detection of minimal residual disease (MRD) to guide the postsurgical clinical management of early colon cancer patients. Moreover, it is important to define if conventional (CAPOX) versus intensive (FOLFOXIRI) adjuvant chemotherapy could convert plasma ctDNA positive into a ctDNA negative status.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Value of ctDNA in the Treatment of Multiple Primary Cancers#840843
- ctDNA and TEP Levels in Colon Cancer#1047760
- Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer#802048
- Liquid Biopsy in Lung Cancer#1114342
- Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer#917494
Record · ID 908278
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive